Skip to main content

30.04.2020 | COVID-19 | Hot Topic | Ausgabe 5/2020 Zur Zeit gratis

Current Oncology Reports 5/2020

COVID-19 and Cancer: a Comprehensive Review

Current Oncology Reports > Ausgabe 5/2020
Rohit Gosain, Yara Abdou, Abhay Singh, Navpreet Rana, Igor Puzanov, Marc S. Ernstoff
Wichtige Hinweise
Rohit Gosain and Yara Abdou contributed equally to this work.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.


Purpose of Review

The outbreak of the novel coronavirus disease 2019 (COVID-19) has emerged to be the biggest global health threat worldwide, which has now infected over 1.7 million people and claimed more than 100,000 lives around the world. Under these unprecedented circumstances, there are no well-established guidelines for cancer patients.

Recent Findings

The risk for serious disease and death in COVID-19 cases increases with advancing age and presence of comorbid health conditions. Since the emergence of the first case in Wuhan, China, in December 2019, tremendous research efforts have been underway to understand the mechanisms of infectivity and transmissibility of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), a fatal virus responsible for abysmal survival outcomes. To minimize the mortality rate, it becomes prudent to identify symptoms promptly and employ treatments appropriately. Even though no cure has been established, multiple clinical trials are underway to determine the most optimal strategy. Managing cancer patients under these circumstances is rather challenging, given their vulnerable status and the aggressive nature of their underlying disease.


In this comprehensive review, we discuss the impact of COVID-19 on health and the immune system of those affected, reviewing the latest treatment approaches and ongoing clinical trials. Additionally, we discuss challenges faced while treating cancer patients and propose potential approaches to manage this vulnerable population during this pandemic.

Nutzen Sie Ihre Chance: Dieser Inhalt ist zurzeit gratis verfügbar.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Unsere Produktempfehlungen

e.Med Interdisziplinär


Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf

e.Med Onkologie


Mit e.Med Onkologie erhalten Sie Zugang zu CME-Fortbildungen des Fachgebietes Onkologie, den Premium-Inhalten der onkologischen Fachzeitschriften, inklusive einer gedruckten onkologischen Zeitschrift Ihrer Wahl. 

Über diesen Artikel

Weitere Artikel der Ausgabe 5/2020

Current Oncology Reports 5/2020 Zur Ausgabe

Lung Cancer (H Borghaei, Section Editor)

New Targets in Lung Cancer (Excluding EGFR, ALK, ROS1)

Lymphomas (MR Smith, Section Editor)

Hairy Cell Leukaemia

Breast Cancer (B Overmoyer, Section Editor)

Applying the New Guidelines of HER2 Testing in Breast Cancer

Webinare und Artikel zur Corona-Krise

Die aktuelle Entwicklung zu SARS-CoV-2 (2019-nCoV) und der Lungenkrankheit COVID-19 im Überblick. » zum Dossier